The Evaluation of the Therapeutic Efficacy and Side Effects of a Macromolecular Dexamethasone Prodrug in the Collagen-Induced Arthritis Mouse Model

[1]  C. Roux,et al.  Glucocorticoid-induced osteoporosis , 2015, RMD Open.

[2]  S. Goldring,et al.  Macromolecular prodrug of dexamethasone prevents particle-induced peri-implant osteolysis with reduced systemic side effects. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[3]  K. Ulbrich,et al.  Nanomedicines for inflammatory arthritis: head-to-head comparison of glucocorticoid-containing polymers, micelles, and liposomes. , 2014, ACS nano.

[4]  Steven R Goldring,et al.  Development of macromolecular prodrug for rheumatoid arthritis. , 2012, Advanced drug delivery reviews.

[5]  S. Goldring,et al.  Early detection and treatment of wear particle-induced inflammation and bone loss in a mouse calvarial osteolysis model using HPMA copolymer conjugates. , 2011, Molecular pharmaceutics.

[6]  J. Jacobs,et al.  Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis , 2010, Nature Reviews Rheumatology.

[7]  S. Goldring,et al.  Development of a macromolecular prodrug for the treatment of inflammatory arthritis: mechanisms involved in arthrotropism and sustained therapeutic efficacy , 2010, Arthritis research & therapy.

[8]  G. Verbruggen,et al.  A multiparameter approach to monitor disease activity in collagen-induced arthritis , 2010, Arthritis research & therapy.

[9]  R. Vollenhoven,et al.  Treatment of rheumatoid arthritis: state of the art 2009 , 2009, Nature Reviews Rheumatology.

[10]  K. Fu,et al.  Synthesis and Evaluation of a Well-defined HPMA Copolymer–Dexamethasone Conjugate for Effective Treatment of Rheumatoid Arthritis , 2008, Pharmaceutical Research.

[11]  S. Goldring,et al.  Novel dexamethasone-HPMA copolymer conjugate and its potential application in treatment of rheumatoid arthritis , 2007, Arthritis research & therapy.

[12]  A. Mahajan.  Chapter-142 Treatment of Rheumatoid Arthritis State-of-the-Art , 2007 .

[13]  S. Giannini,et al.  High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. , 2006, Bone.

[14]  B. Waksman.  Immune Regulation in Adjuvant Disease and Other Arthritis Models: Relevance to Pathogenesis of Chronic Arthritis , 2002, Scandinavian journal of immunology.

[15]  Bendele Am.  Animal models of rheumatoid arthritis. , 2001 .

[16]  Edward F. Rosloniec,et al.  Collagen‐Induced Arthritis , 1996, Current protocols in immunology.

[17]  Kay Dickersin,et al.  Osteoporosis prevention, diagnosis, and therapy. , 2000, NIH consensus statement.

[18]  S. Ikuyama,et al.  Glucocorticoid-induced osteoporosis: pathogenesis and management , 2000, Journal of Bone and Mineral Metabolism.

[19]  M. Goldstein,et al.  Chronic glucocorticoid therapy-induced osteoporosis in patients with obstructive lung disease. , 1999, Chest.

[20]  M. Drezner,et al.  Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee , 1987, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  L. Sokoloff,et al.  Animal models of rheumatoid arthritis. , 1984, International review of experimental pathology.

[22]  C. Werning.  [Rheumatoid arthritis]. , 1983, Medizinische Monatsschrift fur Pharmazeuten.